Radiolabeled somatostatin analogues therapy in advanced neuroendocrine tumors: A single centre experience

A. Filice, A. Fraternali, A. Frasoldati, M. Asti, E. Grassi, L. Massi, M. Sollini, A. Froio, P. A. Erba, A. Versari

Research output: Contribution to journalArticlepeer-review


The aim of this study was to assess the efficacy of PRRT in patients with advanced neuroendocrine tumors (NETs). Patients and Methods. From January 2007 to August 2011, we enrolled 65 patients (m/f 38/27; mean age 65 years, range 3383) with advanced NETs having enhanced SSTR expression, treated with PRRT. The enhanced expression of SSTR was assessed using 68Ga-DOTATOC/DOTATATE PET/CT. Among all the enrolled patients, 6 of them were excluded from the present analysis since they voluntarily interrupted treatment. Mean activity/cycle of 2.6 GBq ( 90Y-DOTATOC/DOTATATE) or 6.0 GBq ( 177Lu-DOTATOC/DOTATATE) was administrated intravenously (max 9 cycles). Results. Complete response (CR) was found in 1/59 (2%) patients, partial remission (PR) in 24/59 (40.5%) patients, stable disease (SD) in 24/59 (40.5%), and progression (PD) in 10/59 (17%) patients. The overall tumor response rate (CR + PR) was 42.5. In 40.5 of patients, the disease could be stabilized. Overall, 49 out of 59 patients had no tumor progression (83%). Twelve patients out of 59 (20%) had grade 2-3 hematological side effects including anemia, thrombocytopenia, and leukopenia. Long-term nephrotoxicity was observed in 3 patients (2 moderate, 1 severe). Conclusions. PRRT is a promising perspective for patients with advanced NETs.

Original languageEnglish
Article number320198
JournalJournal of Oncology
Publication statusPublished - 2012

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Radiolabeled somatostatin analogues therapy in advanced neuroendocrine tumors: A single centre experience'. Together they form a unique fingerprint.

Cite this